Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial

STOP-COVID19 Investigators, Holly R. Keir, Merete B. Long, Hani Abo-Leyah, Yan Hui Giam, Thenmalar Vadiveloo, Thomas Pembridge, Rebecca C. Hull, Lilia Delgado, Margaret Band, Fiona McLaren-Neil, Simon Adamson, Eva Lahnsteiner, Amy Gilmour, Chloe Hughes, Benjamin JM New, David Connell, Rebecca Dowey, Helena Turton, Hollian RichardsonDiane Cassidy, Jamie Cooper, Jay Suntharalingam, Lavanya Diwakar, Peter Russell, Jonathan Underwood, Alexander Hicks, Davinder Dosanjh, Beth Sage, Devesh Dhasmana, Mark Spears, AA Roger Thompson, Christopher Brightling, Andrew Smith, Manish Patel, Jacob George, Alison M. Condliffe, Amelia Shoemark, Graeme MacLennan, James D. Chalmers*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science